Articles
Protecting a biotechnology or pharmaceutical invention often comes down to one critical factor: your filing date. In the world of patent law, even a single day can mean the difference between securing your intellectual property and losing it to a competitor. One of the most overlooked yet deeply important aspects of this process is managing your sequence listing priority claim correctly. Whether you are filing under the Patent Cooperation Treaty (PCT) or through a national/regional patent office, understanding how sequence listing priority claims work is not just helpful — it is essential. This article breaks down everything you need to know in simple, clear language so you can protect your invention without missing a beat.
A sequence listing priority claim refers to the process by which a patent applicant claims the benefit of an earlier filing date — known as the priority date — for an application that includes biological sequence data such as nucleotide or amino acid sequences.
When you file a patent application containing sequence data, patent offices require that this data be submitted in a standardized, machine-readable format. Previously, this was done using WIPO Standard ST.25. However, since July 2022, the new WIPO Standard ST.26 has become mandatory worldwide for all new applications.
The priority claim connects your new application back to an earlier application (the “priority application”) so that your invention is evaluated as if it were filed on that earlier date. This matters enormously in competitive fields like genomics, bioinformatics, and drug development.
A proper sequence listing priority claim must satisfy two conditions simultaneously:
If either condition fails, your priority date may be lost — and that can be a fatal blow to your patent rights.
Your filing date is your legal timestamp. It determines who invented first (in first-to-file systems like the US, EU, and most of the world), what prior art can be used against you, and whether your application survives validity challenges.
In the context of a sequence listing priority claim, losing your priority date means your application will be examined against all documents published between your original filing date and your new filing date. Competitors, academic publications, or even your own disclosures during that gap can suddenly become prior art that kills your patent.
Here is what is at risk when a sequence listing priority claim is not handled properly:
The good news is that these risks are entirely preventable with the right knowledge and process in place.
Understanding the rules is the first step toward protecting your filing date. Below are the core requirements that every applicant must follow:
All applications filed on or after July 1, 2022 must include sequence data in ST.26 XML format. Applications that claimed priority from an ST.25-formatted earlier application must convert the sequence listing to ST.26 for the new filing. This conversion must be accurate and complete – any discrepancy between the priority application and the new filing can raise issues during examination.
Under the Paris Convention, a sequence listing priority claim must generally be filed within 12 months of the earliest priority application. For PCT applications, this window is also 12 months from the first filing. Missing this deadline eliminates your right to claim priority, unless a restoration of priority rights is granted, which is not guaranteed.
The sequence listing must be incorporated into the application as filed. It cannot be added later without consequences. If it is missing at the time of filing, the applicant may receive a filing date of the date when the sequence listing is eventually submitted, not the original filing date.
The priority claim must be explicitly stated in the application. This includes the country of the earlier application, the filing date, and the application number. In PCT applications, this is done on the Request form (PCT/RO/101). Missing or incorrect details can invalidate the claim.
Even experienced filers make avoidable errors. Here are the most frequent mistakes seen in sequence listing priority claim handling:
Each of these errors has the potential to compromise your sequence listing priority claim and, by extension, your patent rights.
Following a clear, structured approach can eliminate most risks associated with sequence listing priority claims. Here is what the best-prepared applicants do:
The transition from ST.25 to ST.26 has added a new layer of complexity to the sequence listing priority claim process. ST.26 uses XML-based formatting, which is more structured and internationally standardized than its predecessor. While this is a positive development for global harmonization, it requires applicants to be more careful than ever during the priority claiming process.
One key point: if your original priority application was filed under ST.25, the ST.26 sequence listing in your new application must represent the same biological content. Any sequence that was present in the priority document must appear in the new listing. Adding new sequences without proper disclosure can create issues related to added matter or insufficient support.
A sequence listing priority claim is not just a formality – it is a legal instrument that can protect or expose years of research and investment. By understanding the rules, meeting the deadlines, and working with compliant formats like ST.26, you can preserve your filing date with confidence.
If you are unsure about any aspect of your sequence listing priority claim, consulting with a qualified patent professional who specializes in biotechnology filings is always the safest path forward.
At our Sequence Listing Company, we specialize exclusively in creating perfect patent sequence listings for biotechnology and pharmaceutical companies. Founded by patent attorneys and bioinformatics specialists with over 10 years of experience, we understand the critical intersection of scientific innovation and intellectual property protection. Our dedicated team has helped hundreds of companies successfully navigate the complex regulatory requirements of sequence listings across global patent offices. We combine technical precision with regulatory expertise to ensure your valuable innovations receive the protection they deserve without delays or complications.
Effectual Services is an award-winning Intellectual Property (IP) management advisory & Consulting firm.